Talbutal: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Talbutal": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
Line 1: Line 1:
{{drugbox |
{{Drugbox
| IUPAC_name = 5-(1-methylpropyl)-5-(2-propenyl)-<BR>2,4,6(1''H'',3''H'',5''H'')-pyrimidinetrione
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470476789
| IUPAC_name = (RS)-5-allyl-5-''sec''-butylpyrimidine-2,4,6(1''H'',3''H'',5''H'')-trione
| image = Talbutal.svg
| image = Talbutal.svg
| width = 120
| width = 120
<!--Clinical data-->
| tradename = 
| pregnancy_category =
| legal_US = Schedule III
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 115-44-6
| CAS_number = 115-44-6
| ATC_prefix = N05
| ATC_prefix = N05
| ATC_suffix = CA07
| ATC_suffix = CA07
| PubChem = 8275
| PubChem = 8275
| DrugBank =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| C = 11 | H = 16 | N = 2 | O = 3
| DrugBank = DB00306
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 7976
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4YIR8202AX
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200802
 
<!--Chemical data-->
| C=11 | H=16 | N=2 | O=3  
| molecular_weight = 224.256 g/mol
| molecular_weight = 224.256 g/mol
| bioavailability = ?
| smiles = O=C1NC(=O)NC(=O)C1(C(C)CC)C\C=C
| metabolism = ?
| InChI = 1/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
| elimination_half-life = ?
| InChIKey = BJVVMKUXKQHWJK-UHFFFAOYAK
| excretion = ?
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| pregnancy_category = ?
| StdInChI = 1S/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)
| legal_US = Schedule III
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| routes_of_administration = ?
| StdInChIKey = BJVVMKUXKQHWJK-UHFFFAOYSA-N
| synonyms = <small>5-(1-methylpropyl)-5-(2-propenyl)-2,4,6(1''H'',3''H'',5''H'')-pyrimidinetrione</small>
}}
}}


'''Talbutal''' ('''Lotusate&reg;'''), also called 5-allyl-5-sec-butylbarbituric acid, is a [[barbiturate]] with a short to intermediate duration of action. It is a [[structural isomerism|structural isomer]] of [[butalbital]].
'''Talbutal''' ('''Lotusate''') is a [[barbiturate]] with a short to intermediate duration of action. It is a [[structural isomerism|structural isomer]] of [[butalbital]]. Talbutal is a schedule III drug in the U.S.
 
==Pharmacology==
Talbutal is a short to intermediate-acting barbiturate. Barbiturates act as nonselective depressants of the [[central nervous system]] (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce [[anesthesia]].<ref name="Mutschler">{{Cite book|last1=Mutschler|first1=Ernst|last2=Schäfer-Korting|first2=Monika|title=Arzneimittelwirkungen|language=German|location=Stuttgart|publisher=Wissenschaftliche Verlagsgesellschaft|year=2001|edition=8|pages=280ff|isbn=3-8047-1763-2}}</ref>
 
==Mechanism of action==
Talbutal binds at a distinct binding site associated with a Cl<sup>−</sup> ionopore at the [[GABAA receptor|GABA<sub>A</sub> receptor]], increasing the duration of time for which the Cl<sup>−</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
 
==Toxicity==
Symptoms of acute barbiturate poisoning include drowsiness, confusion, coma, respiratory depression, [[hypotension]],<ref name="Mutschler" /> and shock.
 
==References==
{{Refimprove|date=December 2009}}
{{reflist}}


{{Barbiturates}}


{{Hypnotics and sedatives}}
{{Hypnotics and sedatives}}
{{GABAAR PAMs}}
[[Category:Barbiturates]]
[[Category:GABAA receptor positive allosteric modulators]]


{{pharma-stub}}


[[Category:Barbiturates]]
{{sedative-stub}}
[[de:Talbutal]]
{{WikiDoc Sources}}

Revision as of 15:04, 13 April 2015

Talbutal
File:Talbutal.svg
Clinical data
Synonyms5-(1-methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC11H16N2O3
Molar mass224.256 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Talbutal (Lotusate) is a barbiturate with a short to intermediate duration of action. It is a structural isomer of butalbital. Talbutal is a schedule III drug in the U.S.

Pharmacology

Talbutal is a short to intermediate-acting barbiturate. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.[1]

Mechanism of action

Talbutal binds at a distinct binding site associated with a Cl− ionopore at the GABAA receptor, increasing the duration of time for which the Cl− ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

Toxicity

Symptoms of acute barbiturate poisoning include drowsiness, confusion, coma, respiratory depression, hypotension,[1] and shock.

References

  1. ↑ 1.0 1.1 Mutschler, Ernst; Schäfer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. pp. 280ff. ISBN 3-8047-1763-2.


Template:GABAAR PAMs


Template:Sedative-stub

Retrieved from "https://www.wikidoc.org/index.php?title=Talbutal&oldid=1086638"